Pet friendly community
Thus, substantial and mounting evidence supports a direct contributory role of gut microbiota as a participant in CVD pathogenesis, and preclinical studies indicate that the therapeutic targeting of microbial contributors to the TMAO metaorganismal pathway may hold promise as a novel approach for the prevention or treatment of CVD
So how do you transform a dysfunctional gut into a powerhouse
As we move toward more powerful combinations and oral non-peptides, the goal for the cardiovascular team is now to ensure equitable access to these life-saving tools and to transition from treating obesity to treating cardiometabolic disease. References Health Effects of Overweight and Obesity in 195 Countries over 25 , accessed on January 12, 2026, American College of Cardiology Issues Guidance on Weight , accessed on January 12, 2026, Study Details | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | ClinicalTrials.gov, accessed on January 12, 2026, The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist NIH, accessed on January 12, 2026, Semaglutide and Cardiovascular Outcomes NEJM | Request PDF ResearchGate, accessed on January 12, 2026, GLP-1 receptor agonists and cardiorenal outcomes in type 2 NIH, accessed on January 12, 2026, Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT, accessed on January 12, 2026, Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial PubMed, accessed on January 12, 2026, GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical , accessed on January 12, 2026, Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective, accessed on January 12, 2026, Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists Frontiers, accessed on January 12, 2026, Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program PubMed Central, accessed on January 12, 2026, Semaglutide Effects on Cardiovascular Outcomes in People With , accessed on January 12, 2026, The expanding landscape of GLP-1 medicines
The use of the term dietary mineral is considered archaic since the intent of the term mineral is to describe ions not actual minerals
